The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
 
Salman Rafi Punekar
Research Funding - Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - A2 Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Camurus (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Caleb Joshua Smith
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Diane M. Simeone
Consulting or Advisory Role - FibroGen
Research Funding - Biological Dynamics; Clearnote Health; Immunovia; Micronoma
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
 
Oliver Dorigo
Honoraria - Blueprint Medicines
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; IMV; Merck; PSI CRO Deutschland; R-Pharm
Speakers' Bureau - Immunogen
Research Funding - AstraZeneca (Inst); BioEclipse Therapeutics (Inst); Genentech (Inst); IMV (Inst); Millennium (Inst); Novartis (Inst); PharmaMar (Inst)
 
Leslie R. Boyd
Consulting or Advisory Role - AstraZeneca
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Seagen; Veru
Consulting or Advisory Role - MyCareGorithm
Travel, Accommodations, Expenses - A2Bio
 
Jeffrey Ward
Employment - Millipore (I); Pfizer (I)
Consulting or Advisory Role - Guidepoint Inc; Jazz Pharmaceuticals; Novocure; Takeda
Research Funding - Asher Biotherapeutics (Inst); AstraZeneca (Inst); Genmab (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Novocure (Inst); Pfizer (Inst); Roche/Genentech (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Halozyme; Novocure
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Allogene Therapeutics; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Caribou Biosciences; Cowen; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead Company; Legend Biotech; Novartis; Pfizer; Sana Biotechnology; Umoja Biopharma
Research Funding - 2seventy bio (Inst); Allogene Therapeutics (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Cero Therapeutics (Inst); Kite, a Gilead Company (Inst); Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. (Inst)
Other Relationship - Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee.; Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer
 
Maria Pia Morelli
No Relationships to Disclose
 
Matthew Stephen Block
Research Funding - Alkermes; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Immune Design (Inst); Marker, Inc. (Inst); Merck (Inst); nference; Pharmacyclics (Inst); Regeneron; Sorrento Therapeutics (Inst); TILT Biotherapeutics; Transgene (Inst); Viewpoint Molecular Targeting
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Ramez Nassef Eskander
Consulting or Advisory Role - AstraZeneca/MedImmune; BioNTech SE; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; PMV Pharma; Regeneron; Seagen
Speakers' Bureau - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
Other Relationship - GOG Foundation; The Clearity Foundation
 
Wendy J. Langeberg
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - A2 Biotherapeutics
Other Relationship - A2 Biotherapeutics: Receipt of equipment, materials, drugs, medical writing, gifts or other services
 
Kirstin B. Liechty
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; Ceria Therapeutics
 
Gayanie S. Ong
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
William Y. Go
Employment - A2 Biotherapeutics
Leadership - A2 Biotherapeutics; American Psychiatric Association Foundation; Viewpoint School
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen; Gilead Sciences
 
David G. Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics; NAVAN Technologies
Honoraria - Bristol-Myers Squibb; Caribou Biosciences; Celgene; Genentech; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead Company; Lilly; MustangBio; Novartis; Umoja Biopharma
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead Company (Inst); Legend Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Marcela Valderrama Maus
Leadership - 2Seventy Bio Board of directors
Stock and Other Ownership Interests - 2seventy bio; Century Therapeutics; Genocea Biosciences; NexImmune; Oncternal Therapeutics; TCR2 Therapeutics
Honoraria - ArsenalBio
Consulting or Advisory Role - Adaptimmune; Agenus; Allogene Therapeutics; Arcellx; Astellas Pharma; AstraZeneca; Atara Biotherapeutics; Bayer; Bristol-Myers Squibb; Cabaletta Bio (SAB); Cellectis (SAB); CRISPR therapeutics; Genocea Biosciences; GlaxoSmithKline; In8bio (SAB); Intellia Therapeutics; Kite, a Gilead Company; Micromedicine/BendBio; NexImmune; Novartis; Oncternal Therapeutics; Sanofi; TCR2 (SAB); Tmunity Therapeutics, Inc.; WindMIL (SAB)
Speakers' Bureau - ArsenalBio
Research Funding - Kite, a Gilead Company; Novartis
Patents, Royalties, Other Intellectual Property - Multiple, owned by Massachusetts General Hospital; Novartis; Promab
Expert Testimony - Australia FPA
 
John Sutton Welch
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen Oncology (Inst); Notable Labs (Inst)
 
Julian R. Molina
No Relationships to Disclose